NSE: DIVISLAB · 6 October 2026
- Divi's Laboratories Limited shares advanced 3.85% on Tuesday, trading near the upper end of the day's range. The stock opened at ₹9,212.00, touched a high of ₹9,553.50, and a low of ₹9,165.00 before resting at ₹9,550.00.
- Divi's Laboratories Limited successfully conducted its 36th Annual General Meeting through video conferencing. All resolutions set out in the notice, including the adoption of audited financial statements and the approval of a final dividend of ₹30 per equity share for the financial year ended March 31, 2026, were passed with the requisite majority.
- Trading volume was 0.99 times the 20-day average daily volume.
Why is Divi S Laboratories share price rising on 6 October 2026?
Divi's Laboratories Limited shares advanced 3.85% on Tuesday, trading near the upper end of the day's range. The stock opened at ₹9,212.00, touched a high of ₹9,553.50, and a low of ₹9,165.00 before resting at ₹9,550.00.
The broader market and healthcare segments provided a supportive backdrop for the session. The benchmark Nifty rose 0.98%, while the Nifty Pharma sector index outperformed with a gain of 1.66%, benefiting pharmaceutical counters broadly. Divi's Laboratories' upward move outpaced the sector benchmark, aligning with positive sentiment across major active pharmaceutical ingredient manufacturers.
While recent corporate updates include the conclusion of the company's 36th Annual General Meeting on August 10, 2026, and the retirement of senior management personnel effective July 31, 2026, these operational developments offer baseline context rather than a direct trigger for today's price action. The stock's steady advance appears consistent with broader sector strength and institutional participation in large-cap pharmaceutical names.
4.64 lakh shares traded by 6 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 4.68 lakh shares (0.99 times). The five-day average daily volume was 4.48 lakh shares. Separately, the NSE report for 5 October 2026 showed 3.43 lakh shares delivered, representing 71.39% of that day’s traded volume. The same report recorded 40,276 trades.
The stock's 3.85% gain coincided with a strong up-move in the Nifty Pharma sector index and solid delivery participation, suggesting institutional accumulation without a single isolated corporate catalyst.
Latest Company Developments
Divi's Laboratories Limited successfully conducted its 36th Annual General Meeting through video conferencing. All resolutions set out in the notice, including the adoption of audited financial statements and the approval of a final dividend of ₹30 per equity share for the financial year ended March 31, 2026, were passed with the requisite majority.
Formalizes shareholder approval for annual accounts and the dividend payout schedule.
The company announced the cessation of Mr. L. Ramesh Babu, Vice President (Procurement), and Mr. D. Madhu Babu, Vice President (Projects), due to retirement from the close of business hours on July 31, 2026. Both officials stepped down as Senior Management Personnel in accordance with regulatory disclosures.
Marks routine leadership transitions in key operational verticals of procurement and project management.
Divi's Laboratories submitted its standalone and consolidated financial results for the first quarter of financial year 2026-27 to the stock exchanges. The filing provided key metrics on quarterly revenue, operational expenditures, and net profitability.
Provides baseline quarterly earnings visibility for institutional and retail investors.
Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Divi's Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.66% on 30 September 2026. This compares with 13.87% on 30 June 2026, a change of +0.79 percentage points.
The filing reported 49 MF/UTI holders.
What to Watch Next
- Upcoming financial results for the quarter ending September 30, 2026, following the trading window closure effective October 1, 2026.
- Operational ramp-up and capacity utilization trends at the Greenfield Unit 3 facility near Kakinada.
- Sustained delivery volume persistence above the 70% threshold in subsequent trading sessions.
- Regulatory audit updates and compliance developments across manufacturing plants Unit 1 and Unit 2.
Other Dated Coverage
- Why Divi's Lab Shares Fell 3.27% Today: Market Context & Analysis | 1 October 2026 — 1 October 2026
- Why Divi's Lab Shares Fell 1.48% Today: Sector Weakness & Context | 30 September 2026 — 30 September 2026
More Divi S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Divi S Laboratories company news?
Divi's Laboratories Limited successfully conducted its 36th Annual General Meeting through video conferencing. All resolutions set out in the notice, including the adoption of audited financial statements and the approval of a final dividend of ₹30 per equity share for the financial year ended March 31, 2026, were passed with the requisite majority.
How strong was Divi S Laboratories’s trading volume?
4.64 lakh shares traded, 0.99 times the 20-day average daily volume. The price and volume data are dated 6 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Article by: WittyTrades Research Desk
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.